Nephros, Inc. (NASDAQ:NEPH – Get Free Report)’s share price traded down 2.8% during mid-day trading on Monday . The company traded as low as $1.60 and last traded at $1.60. 5,861 shares were traded during trading, a decline of 22% from the average session volume of 7,553 shares. The stock had previously closed at $1.65.
Analyst Upgrades and Downgrades
Separately, Benchmark restated a “speculative buy” rating and issued a $5.00 price target on shares of Nephros in a report on Tuesday, November 12th.
Read Our Latest Analysis on NEPH
Nephros Stock Performance
Nephros (NASDAQ:NEPH – Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.02 EPS for the quarter. Nephros had a negative return on equity of 11.39% and a negative net margin of 6.86%. The firm had revenue of $3.52 million during the quarter.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Nephros stock. Dimensional Fund Advisors LP bought a new position in shares of Nephros, Inc. (NASDAQ:NEPH – Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 17,631 shares of the company’s stock, valued at approximately $37,000. Dimensional Fund Advisors LP owned approximately 0.17% of Nephros at the end of the most recent reporting period. Institutional investors and hedge funds own 41.10% of the company’s stock.
Nephros Company Profile
Nephros, Inc, a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.
Read More
- Five stocks we like better than Nephros
- Stock Splits, Do They Really Impact Investors?
- Mobileye’s High Short Interest Signals Squeeze Potential
- What is Put Option Volume?
- Rivian: Weathering the Storm, Poised for Growth?
- What is the MACD Indicator and How to Use it in Your Trading
- Avient Stock: Manufacturing Play With Double-Digit Upside
Receive News & Ratings for Nephros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros and related companies with MarketBeat.com's FREE daily email newsletter.